Karen Boyd, NP
Adult Health · Oak Park, MINPI 1386642791
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,497 of the $3,929 with a category attached, or 89.0%. It is spread thinly across 17 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,400, 6.0 times the $234 reported in 2021. Among adult health clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$905
- Otsuka America Pharmaceutical, Inc.$566
- Teva Pharmaceuticals USA, Inc.$378
- Indivior Inc.$319
- E.r. Squibb & Sons, L.L.C.$318
- Lundbeck LLC$302
- plus $1K from 11 others
What the payments were for
- Food & beverage$3,49789%
- Education$43211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 53 | $905 |
| Otsuka America Pharmaceutical, Inc. | 46 | $566 |
| Teva Pharmaceuticals USA, Inc. | 8 | $378 |
| Indivior Inc. | 15 | $319 |
| E.r. Squibb & Sons, L.L.C. | 11 | $318 |
| Lundbeck LLC | 16 | $302 |
| Alkermes, Inc. | 17 | $237 |
| Johnson & Johnson | 15 | $237 |
| Vanda Pharmaceuticals Inc. | 18 | $225 |
| AbbVie | 18 | $202 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $71 |
| Supernus Pharmaceuticals, Inc. | 3 | $55 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,929 in reported general payments places this provider in the 90th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 45 | $272,164 |
| Invega SustennaPaliperidone Palmitate | 84 | $250,586 |
| IngrezzaValbenazine Tosylate | 32 | $231,926 |
| Abilify MaintenaAripiprazole | 67 | $191,069 |
| RexultiBrexpiprazole | 94 | $159,863 |
| AustedoDeutetrabenazine | 20 | $131,966 |
| Invega TrinzaPaliperidone Palmitate | 13 | $92,682 |
| PerserisRisperidone | 12 | $36,082 |
| VraylarCariprazine Hcl | 22 | $33,229 |
| FanaptIloperidone | 18 | $30,889 |
| Lurasidone Hcl | 54 | $14,967 |
| Aripiprazole | 218 | $9,766 |
| Aripiprazole OdtAripiprazole | 25 | $8,423 |
| Paliperidone ErPaliperidone | 36 | $7,668 |
| Asenapine Maleate | 33 | $6,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $378 | $404,13065 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $566 | $350,931161 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $237 | $343,26897 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $905 | $231,92632 claims |
| Indivior Inc.Perseris | $319 | $36,08212 claims |
| AbbVieVraylar | $202 | $33,22922 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $225 | $30,88918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 527 adult health providers in Michigan.
Other adult health in Oak Park
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Susanne QuallichAnn Arbor$42K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Deniene KingAnn Arbor$14K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
- Mary KaiserKalamazoo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.